NCT05486247

Brief Summary

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2015

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 4, 2015

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 2, 2022

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 3, 2022

Completed
Last Updated

August 3, 2022

Status Verified

August 1, 2022

Enrollment Period

6.8 years

First QC Date

August 2, 2022

Last Update Submit

August 2, 2022

Conditions

Malignant Glioma

Keywords

Molecular profileMutational status

Outcome Measures

Primary Outcomes (1)

  • The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

    The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

    April 2019 - December 2021

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with diagnosis of high grade glioma treated in 2 centers of the Hellenic Cooperative Oncology Group (HeCOG).

You may qualify if:

  • Diagnosis of high grade glioma based on tissue biopsy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

FFPE tissue section

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Ourania Romanidou

Study Record Dates

First Submitted

August 2, 2022

First Posted

August 3, 2022

Study Start

February 4, 2015

Primary Completion

December 1, 2021

Study Completion

May 1, 2022

Last Updated

August 3, 2022

Record last verified: 2022-08